INS and metabolic dysfunction-associated steatotic liver disease: Hence, medications possess potential pharmacodynamics to increase insulin sensitivity, congregating much attention for utilization for NAFLD or non-alcoholic steatohepatitis (NASH) (the most severe form of NAFLD) [137-141].